Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Stopped early · Phase 2

Conditions studied: Hemoglobinopathies, Anemia, Sickle Cell, Hemoglobin SC Disease, Thalassemia, Thalassemia Major

In brief

The purpose of this study is to find out if using a lower dose of chemotherapy before stem cell transplantation can cure patients of sickle cell anemia or thalassemia while causing fewer severe side effects than conventional high dose chemotherapy with transplantation.

Key facts

Study ID

NCT00034528

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

2

Starts

2001-09-01

Expected to finish

2003-11-01

Last updated by the study team

2013-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients must:
• Have related donors who are identical at 6 human leukocyte antigens (HLA) loci (A, B and DR) by molecular typing
• Have a performance status from 0-2
• Give written informed consent
• Patients with sickle cell disease should have 1 or more of the following:
• Acute chest syndrome requiring recurrent hospitalization or exchange transfusion
• Nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours
• Recurrent vaso-occlusive pain (2 episodes or more per year) or recurrent priapism
• Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30-50 percent of normal predicted value)
• Bilateral proliferative retinopathy and major visual impairment in at least 1 eye
• Osteonecrosis of multiple joints
• Patients with thalassemia should have 1 or more of the following:
• Transfusion dependence, defined as a transfusion requirement of greater than or equal to 6 units of packed red blood cells over the past 12 months
• Iron overload, defined as serum ferritin greater than 500 mcg/L in the absence of infection or biopsy-proven iron overload
• Presence of 2 or more alloantibodies against red cell antigens

You may not qualify if…

• Pregnancy
• Acute hepatitis (transaminases greater than 3 times the normal value)
• Cardiac ejection fraction less than 30 percent
• Severe renal impairment (glomerular filtration rate less than 30 percent of predicted normal value)
• Severe residual functional neurologic impairment (other than hemiplegia alone)
• Seropositivity for the human immunodeficiency virus (HIV)

Where it is running

• Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.